VICTORIA, Feb. 10, 2015 /CNW/ - T-Bird Pharma Inc.
(TSXV:TPI) ("T-Bird" or the "Company"), a
pharmaceutical company focused on developing premium quality
medical marijuana products and a licensed producer ("LP") under the
Marihuana for Medical Purposes Regulations (Canada) ("MMPR"), wishes to announce that its
wholly owned subsidiary Thunderbird Biomedical Inc. has received a
notice from Health Canada dated February 6,
2015 confirming the renewal of its production license at the
Company's production facility in Saanich,
British Columbia.
"We are very pleased about the successful renewal of our
production license. We are also confident that we will be
securing a sales license in the near future and we are looking
forward to providing the highest quality medicinal marijuana to
Canadian patients. Additionally, I am proud of our team's efforts
within the highly regulated MMPR, which includes completing
multiple extensive Health Canada inspections resulting in
Thunderbird Biomedical Inc. successfully securing this Health
Canada license renewal." Said Dr. Bin Huang, President and CEO of
T-Bird Pharma Inc. "2015 will be a very exciting year for
Thunderbird Biomedical as we begin to expand our operations.
We look forward to providing additional updates over the coming
months."
About T-Bird and Thunderbird
T-Bird Pharma Inc. is the parent company of Thunderbird
Biomedical Inc., a wholly owned private subsidiary formed in
January, 2013. The principal activities of Thunderbird are
the production of marijuana from its Victoria, British Columbia production
facility, as regulated by the Marihuana for Medical Purposes
Regulations (Canada).
Thunderbird obtained a medical marijuana license to undertake the
production of medical marijuana in February
2014, being the fifth company in Canada to obtain such a license.
Thunderbird was acquired by T-Bird in September, 2013.
ON BEHALF OF THE BOARD
"Dr. Bin Huang"
CEO and Director
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Cautionary Statements Regarding Forward Looking
Information
Certain statements in this press release constitute
forward-looking statements, within the meaning of applicable
securities laws. All statements that are not historical
facts, including without limitation, statements regarding future
estimates, plans, programs, forecasts, projections, objectives,
assumptions, expectations or beliefs of future performance, are
"forward-looking statements".
We caution you that such "forward-looking statements" involve
known and unknown risks and uncertainties that could cause actual
and future events to differ materially from those anticipated in
such statements.
Forward-looking statements include, but are not limited to,
statements with respect to commercial operations, including
production and sales of medical marijuana, anticipated revenues,
projected size of market, quantities of future medical marijuana
production, completion of production facilities and other
information that is based on forecasts of future results, estimates
of amounts not yet determinable and assumptions of management.
T-Bird Pharma Inc. (the "Company") does not intend, and
does not assume any obligation, to update these forward-looking
statements except as required by law. These forward-looking
statements involve risks and uncertainties relating to, among other
things, results of production and sale activities, the Company's
historical experience with medical marijuana operations, uninsured
risks, regulatory changes, availability of production facilities,
timeliness of government approvals and the granting of permits and
licenses, changes in prices, actual operating and financial
performance of facilities, equipment and processes relative to
specifications and expectations. Actual results may differ
materially from those expressed or implied by such forward-looking
statements.
SOURCE T-Bird Pharma Inc.